JP7348705B2 - トリアゾールグリコール酸オキシダーゼ阻害剤 - Google Patents

トリアゾールグリコール酸オキシダーゼ阻害剤 Download PDF

Info

Publication number
JP7348705B2
JP7348705B2 JP2021521945A JP2021521945A JP7348705B2 JP 7348705 B2 JP7348705 B2 JP 7348705B2 JP 2021521945 A JP2021521945 A JP 2021521945A JP 2021521945 A JP2021521945 A JP 2021521945A JP 7348705 B2 JP7348705 B2 JP 7348705B2
Authority
JP
Japan
Prior art keywords
triazole
pharmaceutically acceptable
alkyl
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021521945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530560A (ja
JP2021530560A5 (https=
JPWO2020010309A5 (https=
Inventor
マーク ハンス
ザビエル フェルナンデス ミゲル
ザンボーニ ロバール
アクバリロマーニ エルハム
ボーリュー マーク－アンドレ
ルブラン イーブ
サクール パラビ
Original Assignee
カンテロ セラピューティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カンテロ セラピューティクス，インコーポレイティド filed Critical カンテロ セラピューティクス，インコーポレイティド
Publication of JP2021530560A publication Critical patent/JP2021530560A/ja
Publication of JP2021530560A5 publication Critical patent/JP2021530560A5/ja
Publication of JPWO2020010309A5 publication Critical patent/JPWO2020010309A5/ja
Application granted granted Critical
Publication of JP7348705B2 publication Critical patent/JP7348705B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021521945A 2018-07-06 2019-07-05 トリアゾールグリコール酸オキシダーゼ阻害剤 Active JP7348705B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862694918P 2018-07-06 2018-07-06
US62/694,918 2018-07-06
US201962827573P 2019-04-01 2019-04-01
US62/827,573 2019-04-01
PCT/US2019/040690 WO2020010309A1 (en) 2018-07-06 2019-07-05 Triazole glycolate oxidase inhibitors

Publications (4)

Publication Number Publication Date
JP2021530560A JP2021530560A (ja) 2021-11-11
JP2021530560A5 JP2021530560A5 (https=) 2022-07-13
JPWO2020010309A5 JPWO2020010309A5 (https=) 2022-07-13
JP7348705B2 true JP7348705B2 (ja) 2023-09-21

Family

ID=67441692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521945A Active JP7348705B2 (ja) 2018-07-06 2019-07-05 トリアゾールグリコール酸オキシダーゼ阻害剤

Country Status (14)

Country Link
US (2) US11401246B2 (https=)
EP (1) EP3817816A1 (https=)
JP (1) JP7348705B2 (https=)
KR (1) KR102865323B1 (https=)
CN (1) CN112399873B (https=)
AU (1) AU2019297523B2 (https=)
BR (1) BR112021000050A2 (https=)
CO (1) CO2021001277A2 (https=)
IL (1) IL279952B2 (https=)
MX (1) MX2021000051A (https=)
PE (1) PE20210859A1 (https=)
SA (1) SA521420951B1 (https=)
SG (1) SG11202012930RA (https=)
WO (1) WO2020010309A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021000050A2 (pt) 2018-07-06 2021-04-06 Orfan Biotech Inc. Inibidores de triazol glicolato oxidase
AU2020376792B2 (en) 2019-11-01 2025-10-02 Lilac Therapeutics, Inc. Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
EP4087836B1 (en) * 2020-01-08 2025-10-08 Cantero Therapeutics, Inc. Processes for preparing triazole glycolate oxidase inhibitors
WO2022066933A1 (en) * 2020-09-24 2022-03-31 Chinook Therapeutics Canada, Inc. Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof
JP2024538054A (ja) * 2021-10-11 2024-10-18 カンテロ セラピューティクス，インコーポレイティド 高シュウ酸尿症及び腎結石の治療のための１ｈ－１，２，３－トリアゾール－４－カルボン酸
WO2024109917A1 (zh) * 2022-11-25 2024-05-30 西藏海思科制药有限公司 一种三唑衍生物及其在医药上的应用
WO2024212137A1 (en) * 2023-04-12 2024-10-17 Cantero Therapeutics, Inc. Crystalline forms of a 1h-1, 2, 3-triazole-4-carboxylic acid compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100266A1 (en) 2015-12-07 2017-06-15 Wake Forest University Health Sciences Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones
JP2021509401A (ja) 2017-12-29 2021-03-25 ビオマリン プハルマセウトイカル インコーポレイテッド 疾患の治療のためのグルコール酸オキシダーゼ阻害剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0774218B2 (ja) * 1987-03-02 1995-08-09 第一製薬株式会社 ベンゾピラノトリアゾ−ル誘導体
US6187326B1 (en) 1998-12-29 2001-02-13 Thomas T. Yamashita Soil amendment composition
US7022702B2 (en) 2000-04-07 2006-04-04 Qlt Inc. Antiproliferative 1,2,3-thiadiazole compounds
CA2546353A1 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
CN101307307A (zh) * 2008-07-11 2008-11-19 华东理工大学 一种乙醇酸氧化酶制剂、制备方法及应用
WO2013104573A1 (en) 2012-01-10 2013-07-18 F. Hoffmann-La Roche Ag Pyridazine amide compounds and their use as syk inhibitors
JP5455279B1 (ja) 2012-10-25 2014-03-26 アサヒグループホールディングス株式会社 ラテックスの増産方法
WO2014113485A1 (en) 2013-01-15 2014-07-24 Intermune, Inc. Lysophosphatidic acid receptor antagonists
US9392796B2 (en) 2013-03-15 2016-07-19 Spogen Biotech Inc. Plant growth-promoting bacteria and methods of use
FR3021843B1 (fr) 2014-06-06 2016-07-08 Lesaffre & Cie Methode et composition pour ameliorer la productivite de plantes non legumineuses
JP5866035B1 (ja) 2015-01-08 2016-02-17 アサヒグループホールディングス株式会社 有効分げつ促進方法
JP7148241B2 (ja) 2015-03-19 2022-10-05 三菱商事ライフサイエンス株式会社 植物の生長促進や根伸長促進効果且つ付加価値向上効果を有する酵母抽出物
EP3731840A4 (en) 2017-12-29 2021-09-15 Orfan Biotech Inc. NADPH OXIDASE INHIBITORS AND THEIR USE
US11389456B2 (en) 2018-02-23 2022-07-19 Oxalurx, Inc. Compounds and methods for treating oxalate-related diseases
BR112021000050A2 (pt) 2018-07-06 2021-04-06 Orfan Biotech Inc. Inibidores de triazol glicolato oxidase
CA3143334A1 (en) 2019-06-19 2020-12-24 Biomarin Pharmaceutical Inc. Glycolate oxidase inhibitors for the treatment of disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100266A1 (en) 2015-12-07 2017-06-15 Wake Forest University Health Sciences Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones
JP2021509401A (ja) 2017-12-29 2021-03-25 ビオマリン プハルマセウトイカル インコーポレイテッド 疾患の治療のためのグルコール酸オキシダーゼ阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DEREK R. BUCKLE; ET AL，STUDIES ON V-TRIAZOLES. 7. ANTIALLERGIC 9-OXO-1H,9H-BENZOPYRANO[2,3-D]-V-TRIAZOLES，JOURNAL OF MEDICINAL CHEMISTRY，米国，1983年02月，NOL:26,NR:2，PAGE(S):251-254，https://doi.org/10.1021/jm00356a025

Also Published As

Publication number Publication date
IL279952A (en) 2021-03-01
AU2019297523B2 (en) 2025-04-17
EP3817816A1 (en) 2021-05-12
CN112399873B (zh) 2024-10-25
BR112021000050A2 (pt) 2021-04-06
SG11202012930RA (en) 2021-01-28
PE20210859A1 (es) 2021-05-18
KR20210041564A (ko) 2021-04-15
WO2020010309A9 (en) 2020-01-30
US20230143491A1 (en) 2023-05-11
US20210403439A1 (en) 2021-12-30
KR102865323B1 (ko) 2025-09-26
US11401246B2 (en) 2022-08-02
WO2020010309A1 (en) 2020-01-09
JP2021530560A (ja) 2021-11-11
MX2021000051A (es) 2021-03-25
CN112399873A (zh) 2021-02-23
AU2019297523A1 (en) 2021-02-25
IL279952B1 (en) 2024-07-01
CA3104529A1 (en) 2020-01-09
IL279952B2 (en) 2024-11-01
CO2021001277A2 (es) 2021-04-30
SA521420951B1 (ar) 2024-03-24

Similar Documents

Publication Publication Date Title
JP7348705B2 (ja) トリアゾールグリコール酸オキシダーゼ阻害剤
US11013726B2 (en) Substituted pyridinone-containing trycyclic compounds, and methods using same
WO2023062575A1 (en) Cyclic vinyl sulfone compounds as wrn inhibitors
KR101593288B1 (ko) 항균제로서 유용한 플루오로-피리디논 유도체
ES3043183T3 (en) Compounds and uses thereof
US10017491B2 (en) Compounds and uses thereof for the modulation of hemoglobin
US20230322704A1 (en) Compounds and uses thereof for the modulation of hemoglobin
JP2024514844A (ja) Ｍｙｔ１阻害剤を含む併用治療
WO2019191624A1 (en) Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
JP2022068252A (ja) Ｐｒｃ２阻害剤
US7807684B2 (en) HIV reverse transcriptase inhibitors
KR20220003173A (ko) 화합물 및 이의 용도
WO2007037534A1 (ja) ２－へテロアリール置換インドール誘導体
BRPI0714880A2 (pt) inibidores da transcriptase reversa do hiv
EA030410B1 (ru) Замещенные конденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
US20210171503A1 (en) Glycolate oxidase inhibitors and use thereof
ES3049309T3 (en) Processes for preparing triazole glycolate oxidase inhibitors
KR20230016646A (ko) 치환된 피라졸릴 화합물 및 이의 사용 방법
WO2015024016A2 (en) 2-piperidinyl substituted n,3-dihydroxybutanamides
CA3254067A1 (en) STAT3 INHIBITOR MEDICINES
CA3104529C (en) Triazole glycolate oxidase inhibitors
US20230295110A1 (en) Phd inhibitor compounds, compositions, and methods of use
CN118994047B (zh) 一种水杨醛衍生物及其用途
EP3455220A1 (en) Modulators of indoleamine 2,3-dioxygenase
WO2025096495A1 (en) Aryl fluorosulfate-based inhibitors as novel antitubercular agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220705

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230808

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230906

R150 Certificate of patent or registration of utility model

Ref document number: 7348705

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150